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a b s t r a c t
A 66-year-old man underwent a second ablation for atrial ﬁbrillation (AF). Intravenous isoproterenol
administration caused the atrial premature beat (APB), triggering AF. The APB originated in the right
atrium and invariably initiated AF. Therefore, contact activation mapping could not be performed
without frequent electrocardioversion. To prevent the initiation of AF without inhibiting the APB ﬁring,
we administered nifekalant intravenously, which facilitated precise activation mapping and ablation of
the AF-triggering APB. The administration of nifekalant may improve clinical outcomes of catheter
ablation for AF triggered by non-pulmonary vein APB, which invariably initiates AF.
& 2014 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Ablation of the atrial premature beats (APBs) that trigger atrial
ﬁbrillation (AF) is an essential procedure for patients with AF.
However, APBs originating from sites other than the pulmonary
vein (PV) and superior vena cava are often difﬁcult to eliminate.
In some patients, these APBs invariably initiate AF, and frequent
electrocardioversion is required for activation mapping. Here, we
demonstrate a useful effect of nifekalant in a difﬁcult case.
2. Case report
A 66-year-old man with a history of hypertension and sympto-
matic paroxysmal AF underwent extensive encircling PV isolation.
However, after the initial successful PV isolation, he developed
multiple episodes of paroxysmal AF after 3 months of blanking
periods. Six months later, he underwent a second catheter abla-
tion. After conﬁrming electrical isolation of the 4PVs, intravenous
isoproterenol (1.7 and 3.4 mg/min) was administered. This pro-
voked frequent APBs originating from the right atrium (Fig. 1).
These APBs invariably initiated a sustained AF. Therefore, contact
activation mapping using the CARTO system (Biosense Webster
Inc, Diamond Bar, California, USA) could not be performed without
frequent electrocardioversion. To avoid the initiation of AF, we
administered nifekalant (0.2 mg/kg bolus followed by continuous
injection of 0.2 mg/kg/h) in addition to isoproterenol. This resulted
in the maintenance of frequent APB ﬁring without the initiation of
AF (Fig. 2), allowing completion of activation mapping of both
the sinus beat and APB, which was located 14 mm away from the
sinus node at the right atrial free wall (Fig. 3). Radiofrequency
ablation was delivered cautiously with an irrigated tip catheter at a
power of 25 W for 45 s, which eliminated the APB. During the
6-month follow-up period, no AF recurrence or sinus node
dysfunction was observed, and the patient was not taking any
antiarrhythmic drugs.
3. Discussion
We successfully prevented the initiation of AF without inhibit-
ing the AF-triggering APB, and eliminated the AF-triggering APB
located close to the sinus node without damage to sinus node
function. Nifekalant is an IKr antagonist that prolongs the duration
of myocardial action potential and prevents the initiation and
persistence of arrhythmias, including AF, by the mechanism of
reentry and triggered activity [1]. However, it does not directly
affect myocardial depolarization, and therefore does not decrease
the frequency of APBs that are initiated by abnormal automaticity,
such as isoproterenol-induced APB.
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The successful elimination of non-PV AF-triggering APBs would
improve the clinical outcome of AF ablation [2]. However, this can
be challenging because APBs are rarely provoked, even after
administration of isoproterenol. In addition, the administration
of isoproterenol can easily result in the initiation of AF triggered by
the APBs, which can hinder precise contact activation mapping.
However, our observations can improve the clinical outcomes of
ablation in patients with non-PV APBs, which initiate AF.
In summary, this case report describes that the administration
of nifekalant during activation mapping of non-PV AF-triggering
APBs prevented the initiation of AF without inhibiting APBs.
Nifekalant may improve the clinical outcomes of catheter ablation
for AF triggered by non-PV APBs, which invariably initiate AF.
However, additional studies are required to determine whether
this method is widely applicable.
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Fig. 1. (A) Atrial premature beat (APB) initiating atrial ﬁbrillation (AF). Surface
(II and V1) and intracardiac electrograms from the right atrium (RA) and coronary
sinus (CS) are shown. After administration of isoproterenol, frequent APBs origi-
nated from the RA. However, these APBs invariably deteriorated into sustained AF
and activation map could not be performed. (B) Electrodes from the left anterior
oblique projection. A decapolar deﬂectable catheter was positioned in the RA
around the tricuspid annulus. Another decapolar deﬂectable catheter was posi-
tioned in the coronary sinus.
Fig. 2. Inhibition of atrial ﬁbrillation (AF) initiation by nifekalant. Surface (II and V1)
and intracardiac electrograms from the right atrium (RA), ablation catheter (ABL)
positioned at the earliest activation site in the RA, and the coronary sinus (CS) are
shown. After administration of nifekalant in addition to isoproterenol, frequent
atrial premature beat ﬁring remained without initiating AF.
Fig. 3. The activation map of the AF-triggering APB on the CARTO system. This map
demonstrated a centrifugal activation sequence with the earliest site at the right
atrial free wall, 14 mm away from the sinus node (yellow tag). Radiofrequency
ablation was delivered with an irrigated tip catheter at a power of 25 W for 45 s
(red tag).
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